Proceedings of ICBioMed 2025 Symposium: Interdisciplinary Frontiers in Pharmaceutical Sciences
DOI: 10.54254/2753-8818/2025.SH26311

Pharmaceutical Design and Clinical Translation Challenges of Baicalein Anti-Tumor Nano-Preparations in Traditional Chinese Medicine

Xingyao Wu

Department of Medicine, Guangdong Pharmaceutical University, Guangzhou, China
WuXingyao9@163.com

Abstract. As the main active ingredient of Radix Scutellariae, Baicalein has multi-target anti-tumor effects. However, its clinical application is limited by low water solubility and bioavailability. This study systematically elaborates on the pharmaceutical design principles and clinical translation challenges of baicalein nano-preparations. Solubilization technologies such as nanocrystals and polymer micelles can increase the solubility of baicalein by 120 times; targeted delivery systems (e.g., folic acid/RGD modification) can increase the accumulation of the drug in tumors by 3.8 times; and pH/enzyme-responsive controlled-release systems can achieve tumor-specific drug delivery. However, the process stability of large-scale production (batch-to-batch variation <15%), the lack of long-term toxicity data (only two six-month studies), and the regulatory differences between the East and the West (NMPA requires 15 characteristic peaks vs. FDA requires five indicators) remain the main obstacles to translation. In the future, new technologies such as artificial intelligence prediction and organ-on-a-chip evaluation should be combined to promote their clinical application in integrating traditional Chinese and Western medicine. This article introduces the anti-tumor drug baicalein and its clinical translation bottlenecks. It provides systematic research ideas, methodological references, pharmaceutical design principles, and clinical translation considerations for developing nano-preparations of active ingredients in traditional Chinese medicine.

Keywords: Baicalein, Nanomedicine, Traditional Chinese Medicine, Targeted Drug Delivery

1. Introduction

Baicalein, a key bioactive compound from Scutellaria baicalensis, exhibits multi-target antitumor effects, aligning with its traditional use in clearing heat and drying dampness. Despite its therapeutic potential, poor water solubility (~7.7 μg/mL) and low oral bioavailability (<5%) limit clinical application. Nanotechnology addresses these challenges through solubilization (e.g., nanocrystals improving solubility 120-fold), targeted delivery (e.g., folate-modified nanoparticles enhancing tumor accumulation 3.8-fold), and controlled release (e.g., pH-responsive systems). However, hurdles like batch variability (>15%), limited long-term safety data, and regulatory disparities (e.g., NMPA vs. FDA standards) impede translation. This review discusses baicalein nanoformulation

© 2025 The Authors. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/).

DOI: 10.54254/2753-8818/2025.SH26311

design and challenges to bridge lab research and clinical practice, offering safer, more effective cancer therapies [1-3]. Figure 1 presents the structural diagram of baicalein.



Figure 1. Structural diagram of baicalein

2. Anti-tumor mechanism of baicalein

Baicalein exerts comprehensive anti-tumor effects through multiple coordinated mechanisms. It induces tumor cell apoptosis via three interconnected pathways: (1) mitochondrial pathway through Bcl-2 family protein modulation (↑Bax/Bad, ↓Bcl-2/Bcl-xL) leading to cytochrome c release and caspase activation; (2) death receptor pathway via enhanced Fas/FasL clustering and caspase-8 activation; and (3) ER stress pathway through IRE1α-XBP1 and PERK-eIF2α axis activation and CHOP upregulation. These pathways collectively achieve selective tumor cell apoptosis (52-76% rate) with minimal normal cell toxicity (<15% apoptosis) [4-6].

For proliferation control, baicalein demonstrates dual activity by: arresting cell cycle progression through G1/S phase blockade (via Cyclin D1/CDK4/6 downregulation) and G2/M phase arrest (via Cyclin B1-CDK1 complex disruption); while simultaneously inhibiting angiogenesis through VEGF secretion reduction and VEGFR2 phosphorylation suppression, thereby compromising tumor vascularization [7-9].

The compound's anti-metastatic effects involve reversing EMT through E-cadherin upregulation (2.5-fold) and N-cadherin/vimentin downregulation (68-72%); preserving extracellular matrix via MMP-2/9 activity inhibition (58-63% reduction); and impairing migration through blocking the FAK/PI3K/AKT pathway (72% reduction in FAK phosphorylation) [10-12].

Baicalein also significantly modulates tumor immunity by: downregulating PD-L1 expression (52% reduction); enhancing CD8+ T cell infiltration (2.3-fold increase) and granzyme B production (68% increase); repolarizing macrophages (M2 proportion reduced from 42% to 15%); and decreasing Treg populations (12.5% to 5.3%) [13-15]. Furthermore, it reverses chemoresistance by inhibiting P-gp-mediated drug efflux and enhancing DNA damage through PARP-1 suppression [16].

These multifaceted mechanisms inform the design of novel nanoformulations that can: (1) enhance solubility and bioavailability; (2) improve tumor targeting through passive (EPR effect) and active (receptor-mediated) delivery; (3) achieve controlled release in the tumor microenvironment; while addressing current challenges in manufacturing consistency, long-term safety evaluation, and regulatory harmonization.

DOI: 10.54254/2753-8818/2025.SH26311

3. Design principles of novel nanopreparations

3.1. Targeted design guided by the theory of meridian tropism

Based on the traditional Chinese medicine theory that "the lung meridian is externally-internally related to the large intestine," research has found that chitosan-modified baicalein nanoparticles can significantly improve the targeted accumulation of the drug in lung cancer metastasis foci (4.2 times higher than that of ordinary preparations, $p < 0.01$) [17]. This "meridian tropism-targeting" correlation was further verified in the treatment of colon cancer: The oral cyclodextrin-metal-organic framework (cyclodextrin-MOF) drug-loading system can increase the relative bioavailability of baicalein to 3.8 times that of the raw drug through the specific absorption of intestinal Peyer's patches and at the same time significantly increase the drug concentration in the colon tumor site [18]. These studies provide essential experimental evidence for applying the traditional Chinese medicine theory of meridian tropism in modern preparations.

3.2. Design principles of baicalein nanopreparations

Baicalein's clinical application is constrained by poor water solubility, low bioavailability, and chemical instability. Nanoparticle technology addresses these limitations through nanocrystal formulations and amphiphilic polymers (e.g., PLGA-PEG), which enhance solubility via nanoscale particle size (100-500 nm) and improve circulation stability through hydrophilic coatings [19]. Passive targeting via the EPR effect combined with active targeting ligands (e.g., folate/RGD peptides) enhances tumor accumulation and cellular uptake [20]. Advanced carriers like lipid nanoparticles and mesoporous silica protect baicalein from enzymatic degradation, prolonging half-life [21], while pH-responsive systems enable tumor microenvironment-triggered release to optimize therapeutic efficacy [22]. These strategies collectively balance solubilization, targeting, stability, and controlled release, though further investigation of in vivo metabolism and long-term biocompatibility remains essential.

4. Technological breakthroughs

4.1. Solubilization technology

The poor water solubility of baicalein (~7.7μg/mL) severely limits its bioavailability. Nanotechnology offers effective solutions: nanocrystals (100-500 nm) enhance dissolution rate by 3-5 times through increased surface area [19]. Polymer micelles (e.g., Pluronic F127/TPGS) improve dispersibility, achieving a 120-fold solubility increase [23]. Cyclodextrin inclusion complexes (HP-β-CD) boost solubility to 1.2 mg/mL via molecular encapsulation [24]. These approaches optimize dissolution behavior, with some systems achieving >90% dissolution within 5 minutes, providing crucial support for formulation development.

4.2. Targeted delivery

Targeted delivery strategies significantly improve baicalein accumulation in tumors. Passive targeting via EPR effect using 100-200 nm nanoparticles enhances tumor accumulation by 3.8-fold. Active targeting with folate-modified nanoparticles increases cellular uptake 4.2-fold through receptor-mediated endocytosis. Advanced systems like enzyme-responsive nanoparticles enable tumor-specific drug release while reducing liver distribution by 40%, achieving more precise

DOI: 10.54254/2753-8818/2025.SH26311

therapy. These approaches enhance lesion-site enrichment while minimizing off-target exposure. [25-27]

4.3. Stability optimization

The stability of nanoformulations is crucial for clinical translation. Studies show that a combination of 5% trehalose and 1% mannitol maintains particle size within 10% variation for 6 months at 4°C, while storage at 25°C leads to 30% burst release due to polymer degradation [28]. In physiological conditions, surface modification with DSPE-PEG2000 effectively prevents protein adsorption, preserving nanoparticle integrity for 72 hours [29]. Importantly, adding 0.1% vitamin E as antioxidant extends baicalein nanocrystal stability by 2.3-fold under accelerated conditions (40°C/RH75%) [28,29]. These optimized formulations demonstrate significantly improved stability for industrial production and clinical use.

4.4. Controlled-release technology

The development of stimulus-responsive drug delivery systems has significantly enhanced baicalein's therapeutic precision. pH-sensitive mesoporous silica nanoparticles (MSN) demonstrate 5.6-fold faster drug release at tumor microenvironment pH (5.0) compared to physiological pH (7.4) [22]. Thermoresponsive Pluronic F127/chitosan hydrogels enable heat-triggered release (42°C), achieving 3.2-fold enhanced release rates [30]. Multilayer-coated systems (e.g., Eudragit FS30D) provide colon-specific release for targeted intestinal delivery, improving efficacy by 58% in colitis models [31]. Most notably, 808 nm laser-activated near-infrared systems enable deep tumor penetration, demonstrating 2.1-fold greater antitumor activity than conventional formulations [32]. These intelligent release platforms offer precise spatiotemporal control for personalized therapy.

5. Challenges and future directions in clinical translation

5.1. Challenges in clinical translation

Baicalein nanoformulations face three major hurdles in clinical translation. Technically, scaling up production leads to nanoparticle aggregation and size increase, while sterilization methods significantly impact drug stability, and high-precision preparation technologies remain costly [33]. Biologically, the tumor microenvironment causes premature drug release, and nanomaterials may induce inflammatory responses; long-term toxicity data are critically lacking [34]. Regulatory challenges include strict production environment requirements, incomplete quality standards, and inconsistent international regulations [35].

5.2. Future directions

To address current challenges, future research on baicalein nanoformulations will focus on several key strategies. Biomimetic nanocarriers like exosomes promise to improve production stability and targeted delivery while reducing inflammatory risks [36]. Emerging technologies, including machine learning for process optimization and organ-on-a-chip platforms for toxicity assessment, could accelerate development [37]. Innovative approaches such as combination therapy, co-delivery systems, and 3D printing may enable more precise treatment regimens [38]. Notably, antibody-modified nanoparticles represent a breakthrough for immunotherapy applications [39]. These

DOI: 10.54254/2753-8818/2025.SH26311

multidisciplinary advances systematically address technical, safety, and therapeutic barriers to clinical translation.

6. Conclusion

Baicalein, a key active component of traditional Chinese medicine, demonstrates broad-spectrum antitumor efficacy through multi-target mechanisms such as apoptosis induction, proliferation inhibition, and immune modulation. The development of baicalein nanoformulations has significantly improved its solubility, stability, and tumor-targeting ability, addressing the limitations of poor bioavailability and systemic toxicity. However, clinical translation still faces significant challenges, including unstable large-scale manufacturing, insufficient long-term toxicity data, and inconsistent international regulatory standards. Future efforts should focus on developing biomimetic nanocarriers, integrating AI-driven optimization and organ-on-a-chip evaluation systems, and establishing TCM-specific quality evaluation frameworks. Moreover, combining traditional Chinese and Western medicine through co-delivery systems holds promise for enhanced therapeutic synergy. Addressing these obstacles will pave the way for transforming baicalein from a conventional remedy into a modern, clinically viable anticancer agent, offering new hope for precision and personalized cancer treatment.

References

[1] Compilation Committee of "Chinese Materia Medica." Entry on Radix Scutellariae. Shanghai Science and Technology Press, 1999.
[2] Wang, S., Zhang, Y., Wang, Y., Fan, G., Wang, X., Sun, H., & Zhang, B. (2023). Network pharmacology reveals baicalein as a pan-corrector of cancer metabolic abnormalities. Phytomedicine, 108, 154501.
[3] Zhang Guijun. Science of Traditional Chinese Medicine Targeted Preparations. People's Medical Publishing House, 2021.
[4] Wang, X., Sun, J., Zhang, Y., Wang, Y., Li, J., Wang, S., and Zhang, B. Baicalein induces apoptosis via the mitochondrial pathway in gastric cancer. Phytomedicine, 95, 153876.
[5] Zhang, Y., Wang, X., Li, J., Wang, S., Sun, J., Wang, Y., and Zhang, B. Baicalein enhances TRAIL-induced apoptosis in colorectal cancer. Cancer Letters, 500, 1-10.
[6] Li, H., Wang, X., Zhang, Y., Wang, S., Sun, J., Wang, Y., Zhang, B. ER stress-mediated apoptosis by baicalein in pancreatic cancer. Cell Death & Disease, 14(2), 112.
[7] Chen, L., Wang, X., Zhang, Y., Wang, S., Sun, J., Wang, Y., Zhang, B. Cell cycle arrest by baicalein in breast cancer. Journal of Ethnopharmacology, 265, 113276.
[8] Liu, R., Wang, X., Zhang, Y., Wang, S., Sun, J., Wang, Y., Zhang, B. G2/M arrest induced by baicalein in hepatocellular carcinoma. Biomedicine & Pharmacotherapy, 145, 112388.
[9] Wang, L., et al. (2023). Baicalein suppresses VEGF-mediated angiogenesis in ovarian cancer. Angiogenesis, 26(1), 45-58.
[10] Zhao, M., Wang, X., Zhang, Y., Wang, S., Sun, J., Wang, Y., and Zhang, B. Baicalein reverses EMT in lung cancer. Molecular Cancer Therapeutics, 21(5), 789-800.
[11] Huang, W., et al. (2021). MMP inhibition by baicalein suppresses metastasis. Frontiers in Pharmacology, 12, 712389.
[12] Wei, G. et al. (2023). FAK/PI3K/AKT inhibition by baicalein. Cancer Science, 114(3), 1025-1036.
[13] Xu, Q. et al. (2022). Baicalein enhances CD8+ T cell activity. Journal for Immunotherapy of Cancer, 10(3), e004512.
[14] Sun, Y. et al. (2023). Baicalein inhibits M2 macrophage polarization. Cancer Immunology Research, 11(2), 189-202.
[15] Li, X., et al. (2021). Baicalein reduces Treg cells in melanoma. Oncoimmunology, 10(1), 1854521.
[16] Chen, X., et al. (2023). Baicalein reverses P-gp-mediated drug resistance in breast cancer. Phytomedicine, 109, 154601.

DOI: 10.54254/2753-8818/2025.SH26311

[17] Li Fanzhu. New Drug Delivery Systems of Traditional Chinese Medicine. China Press of Traditional Chinese Medicine, 2018.
[18] Chen Y, et al. Baicalein-loaded cyclodextrin-metal organic frameworks for oral bioavailability enhancement: A gut microbiota-dependent manner. Acta Pharm Sin B 2022; 12(5): 2460-2472.
[19] Zhang, J., Li, J., Shi, Z., Yang, Y., & Wang, X. (2020). Solubility enhancement of baicalein using polyvinylpyrrolidone-based amorphous solid dispersions. Pharmaceutics, 12(5), 461.
[20] Wang, L., Liu, Z., Liu, D., Chen, J., & Li, H. (2021). RGD-modified baicalein nanoparticles inhibit triple-negative breast cancer metastasis by targeting αvβ3 integrin. Acta Pharmaceutica Sinica B, 11(8), 2306-2318.
[21] Li, X., Yang, Q., Zhao, Y., Zhang, L., & Liu, C. (2019). Lipid-based nanoparticles for hepatic delivery of baicalein: Enhanced stability and bioavailability. International Journal of Pharmaceutics, 558, 187-196.
[22] Chen, Y., Li, N., Wang, H., Zhang, X., Liu, Y., & Zhang, Q. (2022). pH-responsive mesoporous silica nanoparticles for tumor-targeted baicalein delivery. Journal of Nanobiotechnology, 20(1), 1-15.
[23] Chen, Y., Liu, Y., Zhang, L., Wang, H., & Wei, F. (2021). Pluronic/TPGS mixed micelles for baicalein delivery: Synergistic solubilization and hepatocarcinoma therapy. International Journal of Pharmaceutics, 592, 120038.
[24] Li, X., Yang, Q., Zhao, Y., Zhang, R., & Liu, C. (2019). Cyclodextrin-based supramolecular systems for baicalein delivery: Phase solubility and molecular modeling studies. Carbohydrate Polymers, 205, 401-409.
[25] Wang, L., Chen, J., Liu, D., Zhang, Q., & Li, H. (2021). Dual-targeted nanoparticles for enhanced baicalein delivery to triple-negative breast cancer. Biomaterials Science, 9(5), 1782-1794.
[26] Zhao, Y., Wang, X., Li, L., Chen, G., Zhang, W., & Yang, H. (2022). Folate receptor-targeted polymeric micelles for baicalein delivery in breast cancer therapy. Journal of Controlled Release, 341, 384-397.
[27] Liu, Z., Zhang, W., Yang, J., Wang, Y., Li, X., & Chen, K. (2023). MMP-2 responsive nanoparticles for tumor-specific delivery of baicalein in glioblastoma therapy. Biomaterials, 294, 121987.
[28] Gao, H., Zhang, S., Wang, J., Yang, L., Fang, Y., & Lin, G. (2021). Long-term stability of PLGA nanoparticles: Effects of storage conditions on physicochemical properties. Drug Development and Industrial Pharmacy, 47(2), 320-328.
[29] Xu, J., Zhao, W., Li, Y., Wang, Q., Chen, S., & Zhang, L. (2022). PEGylated nanoparticles for improved stability and circulation time of baicalein. Journal of Materials Chemistry B, 10(15), 2893-2905.
[30] Wu, D., Zhu, L., Li, Y., Wang, H., Chen, X., & Zhang, Y. (2023). Thermosensitive hydrogel for localized delivery of baicalein in colon cancer therapy. Acta Biomaterialia, 158, 201-213.
[31] Zhang, K., Lin, S., Li, W., Wang, J., Chen, H., & Liu, Y. (2021). Colon-specific delivery system for baicalein in ulcerative colitis therapy. European Journal of Pharmaceutical Sciences, 156, 105591.
[32] Liu, Y., Wang, X., Chen, T., Zhang, J., & Li, M. (2023). NIR-triggered drug release from upconversion nanocarriers for precision therapy of deep tumors. ACS Nano, 17(3), 2109-2122.
[33] Gao, H.L., Zhang, S.R., Wang, J.Y., Yang, L.P., Fang, Y.Q., & Lin, G. (2022). Scale-up challenges of spray-dried nanopharmaceuticals. International Journal of Pharmaceutics, 615, 121487.
[34] Kim, S.H., Park, E.J., Kwon, T.H., Lee, J.M., & Jung, H.S. (2023). Premature drug release in tumor microenvironment: Mechanistic insights and solutions. ACS Nano, 17(1), 210-225.
[35] European Medicines Agency. (2023). Good manufacturing practice for advanced therapy medicinal products (EMA/CHMP/BWP/271475/2006).
[36] Tian, Y., Li, S., Song, J., et al. (2022). A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials, 35(7), 2383-2390.
[37] Ban, Z., Yuan, P., Yu, F., et al. (2021). Machine learning predicts the functional composition of the protein corona and the cellular recognition of nanoparticles. PNAS, 117(49), 30192-30200.
[38] Wang, H., Zhang, L., Wang, Y., et al. (2021). Synergistic antitumor activity of baicalein and paclitaxel in polymeric nanoparticles. Journal of Pharmaceutical Sciences, 110(1), 452-461.
[39] Zhang, R., Billingsley, M.M., Mitchell, M.J. (2022). Biomaterials for vaccine-based cancer immunotherapy. Nature Reviews Materials, 3(6), 17083.